Stifel initiated coverage on Artivion with a new price target
$AORT
Medical/Dental Instruments
Health Care
Stifel initiated coverage of Artivion with a rating of Buy and set a new price target of $30.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/23/2024 | $33.00 | Mkt Outperform | JMP Securities |
| 9/27/2022 | $32.00 → $28.00 | Buy | Lake Street |
| 8/8/2022 | $32.00 | Buy | Lake Street |
| 3/3/2022 | $30.00 | Buy | Stifel |
| 2/18/2022 | $39.00 → $30.00 | Buy | Needham |
First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf
Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP constant currency basisAchieved revenue of $388.5 million for the full year of 2024 versus $354.0 million for the full year of 2023, an increase of 10% on a GAAP basis and 9% on a non-GAAP constant currency basisNet loss was $(16.5) million, or $(0.39) per fully diluted share and non-GAAP net income was $0.2 million, or $0.00 per fully diluted share in the fourth quarter of 2024. For the full year, net loss was $(13.4) million, compared to a net loss of $(30.7) million in the 2023 fiscal yearAdju
Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basisNet loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug AdministrationEnrollment completed in NEXUS TRIOMPHE clinical
SC 13G/A - ARTIVION, INC. (0000784199) (Subject)
SC 13G - ARTIVION, INC. (0000784199) (Subject)
SC 13G/A - ARTIVION, INC. (0000784199) (Subject)
Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA, Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023. In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee, who will retire at the end of the year after a successful and long tenure with the Company and a distinguished career in the medical device industry. Artivion also reaffirmed its full-year 2023 financial guidance that was provided on November 2, 2023.
PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST. The items on the agenda of the meeting included the appointment of Dr. Kenneth Macleod as non-executive director of the Company and the approval in accordance with Article 7:151 of the Belgian Companies and Asso
ATLANTA, Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022. "We are excited to welcome Elizabeth to our Board of Directors," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Elizabeth brings a wealth of knowledge in the medical device industry demonstrated by her tenure in the aortic space leading teams focused on the development and commercial launch of innovative healthca
4 - ARTIVION, INC. (0000784199) (Issuer)
4 - ARTIVION, INC. (0000784199) (Issuer)
4 - ARTIVION, INC. (0000784199) (Issuer)
JMP Securities initiated coverage of Artivion with a rating of Mkt Outperform and set a new price target of $33.00
Lake Street reiterated coverage of Artivion with a rating of Buy and set a new price target of $28.00 from $32.00 previously
Lake Street initiated coverage of Artivion with a rating of Buy and set a new price target of $32.00
10-Q - ARTIVION, INC. (0000784199) (Filer)
8-K - ARTIVION, INC. (0000784199) (Filer)
DEFA14A - ARTIVION, INC. (0000784199) (Filer)
4 - ARTIVION, INC. (0000784199) (Issuer)
First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf
30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA, May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS. Patients enrolled were at high risk for open surgical repair
ATLANTA, April 21, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial results will be released on Monday, May 5, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. To listen to the live teleconference, please dial 201-689-8261 a few minutes p
For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA and the Veterans Health Administration announced a new collaboration to jointly develop emergency preparedness and response tools and protocols intended to help increase medical product manufacturing capacity and flexibility, and improve resilie